CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 1.19: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.85BCNY425.82M · vs all stocks (USD)
Revenue (TTM)
378.56MCNY56.49M · vs all stocks (USD)
Profit Margin
-55.16%Beta
0.2660xvs all stocks
52-Week Change
-7.79%vs all stocks
Market Capitalization
2.85BCNY425.82M · vs all stocks (USD)
Enterprise Value
3.28BCNY489.98M · vs all stocks (USD)
Forward P/E
34.83xPrice to Sales (TTM)
7.54xPrice to Book (MRQ)
3.29xEnterprise to Revenue
8.67xEnterprise to EBITDA
-41.87xGross Margin
43.07%Profit Margin
-55.16%Operating Margin
-54.64%Return on Assets (TTM)
-4.73%Return on Equity (TTM)
-21.27%Revenue (TTM)
378.56MCNY56.49M · vs all stocks (USD)
Revenue per Share (TTM)
0.8320CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-59.70%Gross Profit (TTM)
203.63MCNY30.39M · vs all stocks (USD)
EBITDA (TTM)
-78.42MCNY-11.70M · vs all stocks (USD)
Net Income (TTM)
-208.82MCNY-31.16M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-57.02%Operating Cash Flow (TTM)
43.65MCNY6.51M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
76.00MCNY11.34M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
21.51MCNYFY2025 · Dec 31, 2025Revenue
466.12MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
213.48MCNYFY2025 · Dec 31, 2025Gross Profit
252.65MCNYFY2025 · Dec 31, 2025Operating Income
-160.04MCNY-23.88M · vs all stocks (USD)
Pre-tax Income
-259.47MCNYFY2025 · Dec 31, 2025Income Tax Expense
-25.44MCNYFY2025 · Dec 31, 2025Net Income
-234.03MCNYFY2025 · Dec 31, 2025EBIT
-241.61MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-129.97MCNYFY2025 · Dec 31, 2025Research & Development
19.10MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
282.83MCNYFY2025 · Dec 31, 2025Other Operating Expenses
14.20MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
222.60KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
17.87MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5057CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5057CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
455.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
455.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-234.03MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
3.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-127.66MCNYFY2025 · Dec 31, 2025Free Cash Flow
-219.70MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
59.38MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-234.03MCNYFY2025 · Dec 31, 2025Other Non-cash Items
27.50MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
76.19MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.67MCNYFY2025 · Dec 31, 2025Capital Expenditures
-92.04MCNYFY2025 · Dec 31, 2025Other Investing Activity
-52.22KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-92.09MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
252.93MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-314.36MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-16.49MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-77.93MCNYFY2025 · Dec 31, 2025Shares Outstanding
455.12MSharesUpdated Sep 20, 2026Float Shares
334.65MSharesUpdated Sep 20, 2026% Held by Insiders
31.94%vs all stocks
% Held by Institutions
0.93%vs all stocks
Total Cash (MRQ)
17.11MCNY2.55M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0380CNYUpdated Sep 20, 2026Total Debt (MRQ)
426.33MCNY63.62M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4803xCurrent Ratio (MRQ)
0.4550xBook Value per Share (MRQ)
1.91CNYUpdated Sep 20, 2026Total Assets
1.79BCNY267.25M · vs all stocks (USD)
Total Current Assets
304.48MCNYFY2025 · Dec 31, 2025Total Liabilities
869.79MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.49BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
286.30MCNYFY2025 · Dec 31, 2025Total Current Liabilities
583.49MCNYFY2025 · Dec 31, 2025Cash
59.56MCNYFY2025 · Dec 31, 2025Cash Equivalents
193.50KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
59.75MCNYFY2025 · Dec 31, 2025Accounts Receivable
36.77MCNYFY2025 · Dec 31, 2025Inventory
160.12MCNYFY2025 · Dec 31, 2025Accounts Payable
52.71MCNYFY2025 · Dec 31, 2025Short-term Debt
247.22MCNYFY2025 · Dec 31, 2025Other Current Liabilities
4.02MCNYFY2025 · Dec 31, 2025Long-term Debt
199.48MCNYFY2025 · Dec 31, 2025Common Stock (Book)
455.12MCNYFY2025 · Dec 31, 2025Retained Earnings
-519.42MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
921.22MCNY137.46M · vs all stocks (USD)
52-Week Low
5.46CNYUpdated Sep 20, 202652-Week High
15.19CNYUpdated Sep 20, 202652-Week Change
-7.79%vs all stocks
Beta
0.2660xvs all stocks
50-Day MA
6.51CNYUpdated Sep 20, 2026200-Day MA
8.10CNYUpdated Sep 20, 2026Avg 10-Day Volume
11.04MSharesUpdated Sep 20, 2026Avg 30-Day Volume
15.16MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.4600CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.43Profit Margin: -0.55
Financial Health
Altman Z-Score 1.19: grey zoneSignificant
Altman Z-Score: 1.19
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow